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Preoperative chemotherapy for non-small-cell lung cancer: a systematic 
review and meta-analysis of individual participant data 
NSCLC Meta-analysis Collaborative Group 
Summary 
Background 
Individual participant data meta-analyses of postoperative chemotherapy have shown improved 
survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do a systematic review 
and individual participant data meta-analysis to establish the effect of preoperative chemotherapy 
for patients with resectable NSCLC. 
Methods 
We systematically searched for trials that started after January, 1965. Updated individual participant 
data were centrally collected, checked, and analysed. Results from individual randomised controlled 
trials (both published and unpublished) were combined using a two-stage fixed-effect model. Our 
primary outcome, overall survival, was defined as the time from randomisation until death (any 
cause), with living patients censored on the date of last follow-up. Secondary outcomes were 
recurrence-free survival, time to locoregional and distant recurrence, cause-specific survival, 
complete and overall resection rates, and postoperative mortality. Prespecified analyses explored 
any variation in effect by trial and patient characteristics. All analyses were by intention to treat. 
Findings 
Analyses of 15 randomised controlled trials (2385 patients) showed a significant benefit of 
preoperative chemotherapy on survival (hazard ratio [HR] 0·87, 95% CI 0·78–0·96, p=0·007), a 
13% reduction in the relative risk of death (no evidence of a difference between trials; p=0·18, 
I
2
=25%). This finding represents an absolute survival improvement of 5% at 5 years, from 40% to 
45%. There was no clear evidence of a difference in the effect on survival by chemotherapy 
regimen or scheduling, number of drugs, platinum agent used, or whether postoperative 
radiotherapy was given. There was no clear evidence that particular types of patient defined by age, 
sex, performance status, histology, or clinical stage benefited more or less from preoperative 
chemotherapy. Recurrence-free survival (HR 0·85, 95% CI 0·76–0·94, p=0·002) and time to distant 
recurrence (0·69, 0·58–0·82, p<0·0001) results were both significantly in favour of preoperative 
chemotherapy although most patients included were stage IB–IIIA. Results for time to locoregional 
recurrence (0·88, 0·73–1·07, p=0·20), although in favour of preoperative chemotherapy, were not 
statistically significant. 
Interpretation 
Findings, which are based on 92% of all patients who were randomised, and mainly stage IB–IIIA, 
show preoperative chemotherapy significantly improves overall survival, time to distant recurrence, 
and recurrence-free survival in resectable NSCLC. The findings suggest this is a valid treatment 
option for most of these patients. Toxic effects could not be assessed. 
Funding 
Medical Research Council UK. 
Introduction 
Worldwide, roughly 1·5 million new cases of lung cancer are diagnosed annually
1
 with about 85% 
being non-small-cell lung cancers (NSCLCs).
2
 Surgery is thought the best treatment option, but 
only about 20–25% of tumours are suitable for potentially curative resection.3 Two individual 
participant data meta-analyses
4
 showed that postoperative chemotherapy, with or without 
radiotherapy, improved survival. 
Preoperative chemotherapy has the potential to reduce tumour size, increase operability, and 
eradicate micrometastases. Chemotherapy might also be more effective when the blood supply to 
the tumour is still intact before surgical resection, and chemotherapy might be better tolerated if 
patients are not recovering from major surgery. However, preoperative chemotherapy will delay 
surgery, and if ineffective, tumours can become unresectable. 
The findings of several reviews, based on aggregate data from randomised controlled trials,
5, 6, 7, 
8 and 9
 have suggested preoperative chemotherapy improves survival. However, these reviews all 
included different combinations of trials, some of which were confounded by the use of 
chemotherapy in both arms or radiotherapy in one arm, making the specific effects of preoperative 
chemotherapy difficult to discern. Furthermore, analyses of other outcomes and how effects vary by 
patient characteristics were not possible with the aggregate data. Therefore, we did a systematic 
review and meta-analysis of individual participant data to provide more reliable and up-to-date 
evidence on the effect of preoperative chemotherapy on survival and other key outcomes and 
whether this varies by patient subgroup. 
Methods 
Design and study selection 
Methods were prespecified in a protocol (available on request). Randomised trials comparing 
chemotherapy with subsequent surgery versus surgery alone were eligible if they started after Jan 1, 
1965, and aimed to include chemotherapy-naive NSCLC patients, suitable for surgery, without any 
previous malignancy. Trials that planned to use postoperative radiotherapy in both arms, or 
postoperative chemotherapy in the preoperative arm only, were also eligible. 
Published and unpublished trials were sought, with no language restrictions, using randomised trial 
search filters for Medline and Embase
10
 with additional terms for NSCLC and chemotherapy. These 
searches were supplemented by searching trial registers, conference proceedings, review articles, 
and reference lists of trial publications (appendix). Collaborators were asked if they knew of any 
additional trials. Searches were regularly updated until May, 2013. 
Data collection 
For all eligible trials and all patients who were randomised, data were sought on the date of 
randomisation, treatment allocation, type of chemotherapy and number of cycles, age, sex, 
histology, performance status, date of surgery, extent of resection, clinical and pathological tumour 
stage, clinical and pathological response, recurrence, survival, cause of death, and date of last 
follow-up. Standard methods were used to identify missing data and to assess data validity and 
consistency.
11
 Patterns of treatment allocation and the balance of baseline characteristics by 
treatment group were used to check randomisation integrity and follow-up of surviving patients was 
checked to ensure it was up to date and balanced by arm and fed into a risk of bias assessment for 
each trial.
12
 Any inconsistencies were resolved and the final dataset verified by the relevant trial 
contact. 
Definition of outcomes 
Our primary outcome, overall survival, was defined as the time from randomisation until death (any 
cause), with living patients censored on the date of last follow-up. Secondary outcomes were 
recurrence-free survival, time to locoregional and distant recurrence, cause-specific survival, 
complete and overall resection rates, and postoperative mortality. There were concerns that for 
patients receiving their surgery immediately in the surgery-alone arm, any recurrences could be 
identified sooner than in the preoperative chemotherapy arm. This might erroneously suggest a 
benefit of chemotherapy. Thus, analyses of recurrence outcomes were calculated from a landmark 
time of 6 months from the date of randomisation to allow for all patients to have completed their 
allocated treatment.
13
 Events arising within 6 months of randomisation were regarded as events at 
this landmark time. Recurrence-free survival was defined as time from the landmark date until 
locoregional recurrence, distant recurrence, or death, whichever happened first. Patients alive 
without recurrence were censored on the date of last follow-up. To avoid bias from under-reporting 
of subsequent events, time to locoregional (distant) recurrence was defined as time from the 
landmark date to first locoregional (distant) recurrence, and patients experiencing previous distant 
(local) recurrences were censored on the date of distant (local) recurrence. Patients experiencing a 
locoregional and distant recurrence on the same date were counted in both analyses. For trials that 
only recorded the first recurrence, patients having a local (distant) recurrence were censored in the 
analysis of distant (local) recurrence; all other patients without recurrence were censored on the date 
of death or last follow-up. 
We used data on cause of death to assess the effects of chemotherapy on lung and non-lung cancer 
survival. However, although eight trials supplied these data, only two provided sufficiently detailed 
information to discriminate between treatment-related and other non-cancer causes, making it 
impossible to define these outcomes accurately. 
The overall resection rate was defined as the proportion of patients having either a complete or 
incomplete resection. The complete resection rate was defined as the proportion of patients having a 
complete resection. Postoperative mortality was defined as the proportion of patients dying within 
30 days of surgery, and early mortality was defined as death within 6 months of date of 
randomisation, to allow for completion of all treatment in each arm. 
Statistical analysis 
Unless otherwise stated, all analyses were prespecified in the protocol, and done on an intention-to-
treat basis. For time-to-event outcomes, we used the log-rank expected number of events and 
variance to calculate hazard ratio (HR) estimates of effect for each individual trial, which were then 
combined across trials using a stratified-by-trial, two-stage, fixed-effect model.
14
 The random-
effects model
15
 was used to assess the robustness of the results. χ2 heterogeneity tests were used to 
assess differences in the effect of treatment or treatment by covariate interactions across trials. 
Results for time-to-event outcomes are also presented as non-stratified Kaplan-Meier curves.
16
 The 
median follow-up was computed for all patients using the reverse Kaplan-Meier method.
17
 For 
dichotomous outcomes, such as resection rate, the numbers of events and patients were used to 
calculate Peto odds ratio (OR) estimates of effect
14
 for trials, which were then pooled across trials, 
using a fixed-effect model. 
To explore any effect of trial-level characteristics on the effect of chemotherapy, pooled HRs were 
calculated for each prespecified trial group. χ2 tests for interaction and the F ratio were used to 
assess differences in treatment effect across trial groups. To investigate the effect of patient 
characteristics on the effect of chemotherapy, the relevant treatment by patient covariate interaction 
term was included in a Cox regression for each trial. The resulting within-trial interactions (HRs) 
were then pooled across trials using the stratified-by-trial, fixed-effect model. 
18
 These analyses are 
focused on the primary outcome of survival. 
Absolute differences in outcome at 5 years were calculated from the HR and the control group 
baseline event rate.
19
 All p values are two-sided. 
Role of the funding source 
The sponsors of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
Results 
We identified 19 eligible randomised controlled trials; 17 published
20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 
33, 34, 35 and 36
 and two unpublished 
37 and 38
 (appendix). Data could not be supplied for three trials,
34, 
35 and 36
 and one trial only recruited two patients.
37
 Although data were obtained for all 24 patients 
excluded from the investigators' original analyses, and reinstated in this meta-analysis, data for two 
other patients could not be obtained. Therefore, this meta-analysis is based on data from 15 trials
20, 
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 and 38
 (2385 patients), representing 92% of patients who were 
randomised, from all known eligible trials. Any risk of bias associated with the randomisation 
procedure and completeness of outcome data in these 15 trials was judged to be low and the effects 
of early stopping were minimised by the collection of updated follow-up and investigated in the 
analyses. 
Ten trials
22, 24, 25, 26, 27, 28, 29, 30, 32 and 33
 gave chemotherapy only preoperatively and five trials
20, 21, 23, 
31 and 38
 used chemotherapy preoperatively and then postoperatively, usually to responders. All trials 
used platinum-based chemotherapy, except one,
26
 which used docetaxel alone (table 1). Seven 
trials
20, 21, 22, 23, 24, 27 and 32
 used cisplatin, four
29, 30, 33 and 38
 carboplatin, and three
25, 28 and 31
 either 
cisplatin or carboplatin. Eight trials
21, 22, 23, 24, 27, 28, 30 and 33
 used postoperative radiotherapy in both 
arms. 
Table 1.  
Trial characteristics 
 
Accru
al 
years 
Numb
er of 
patien
ts 
Clinic
al 
stage 
Preoperative 
chemotherapy 
used (dose per 
cycle) 
Postoperat
ive 
chemother
apy cycles 
planned 
Postoperat
ive 
radiothera
py planned 
Reach
ed 
target 
accrua
l 
Stopping 
reason 
Medi
an 
follo
w-up 
(years
) 
France 
199020 
1985
–87 
26 I–III 
Cyclophospha
mide (600 
mg/m2), 
vindesine (3 
mg/m2), 
cisplatin (100 
mg/m2); 2 
cycles every 4 
weeks 
2 No No 
High 
progressio
n rate with 
preoperati
ve 
chemother
apy 
3·2 
 Accru
al 
years 
Numb
er of 
patien
ts 
Clinic
al 
stage 
Preoperative 
chemotherapy 
used (dose per 
cycle) 
Postoperat
ive 
chemother
apy cycles 
planned 
Postoperat
ive 
radiothera
py planned 
Reach
ed 
target 
accrua
l 
Stopping 
reason 
Medi
an 
follo
w-up 
(years
) 
MD 
Anderson 
199421 
1987
–93 
60 IIIA 
Cyclophospha
mide (500 
mg/m2; d1), 
etoposide (100 
mg/m2; d1–3), 
cisplatin (100 
mg/m2; d1); 3 
cycles every 4 
weeks 
3 to 
responders 
Yes, if 
surgery 
incomplete 
or 
unresectab
le 
No 
Benefit of 
preoperati
ve 
chemother
apy 
6·7 
Spain 
199422 
1989
–91 
59 IIIA 
Mitomycin (6 
mg/m2), 
ifosfamide (3 
g/m2), cisplatin 
(50 mg/m2); 3 
cycles every 3 
weeks 
0 Yes No 
Benefit of 
preoperati
ve 
chemother
apy 
6·3 
MIP-9123 
1991
–97 
355 I–IIIA 
Mitomycin (6 
mg/m2, d1), 
Ifosfamide (1·5 
g/m2, d1–3), 
cisplatin (30 
mg/m2, d1–3); 
2 cycles every 
3 weeks 
2 to 
responders 
Yes, if 
surgery 
incomplete 
or pT3 or 
pN2 
Yes NA 12·9 
SWOG 
S901538 
1992
–94 
21 I–IIIA 
Etoposide (80 
mg/m2; d1–3), 
carboplatin 
(350 mg/m2; 
d1); 2 cycles 
every 3 weeks 
3 to 
responders 
No No 
Poor 
accrual 
6·3 
JCOG 
920924 
1993
–98 
62 IIIA 
Vindesine (3 
mg/m2; d1,8), 
cisplatin (80 
mg/m2; d1); 3 
cycles every 4 
weeks 
0 
Yes, if 
surgery 
incomplete 
No 
Poor 
accrual 
5·7 
 Accru
al 
years 
Numb
er of 
patien
ts 
Clinic
al 
stage 
Preoperative 
chemotherapy 
used (dose per 
cycle) 
Postoperat
ive 
chemother
apy cycles 
planned 
Postoperat
ive 
radiothera
py planned 
Reach
ed 
target 
accrua
l 
Stopping 
reason 
Medi
an 
follo
w-up 
(years
) 
Netherla
nds 
200025 
1994
–99 
79 IB–II 
Paclitaxel (175 
mg/m2; d1), 
carboplatin 
(AUC=7; d1); 
or teniposide 
(120 mg/m2; 
d1–3), 
cisplatin (80 
mg/m2; d1); at 
least 2 cycles 
every 3 weeks 
0 No No 
Poor 
accrual 
2·2 
Finland 
200326 
1995
–99 
62 III 
Docetaxel (100 
mg/m2; d1); 3 
cycles every 3 
weeks 
0 No No 
Poor 
accrual 
3·1 
MRC 
BLT27 
1995
–
2001 
10 I–III 
Vindesine (3 
mg/m2; d1,8), 
cisplatin (80 
mg/m2; d1); or 
vinorelbine (30 
mg/m2; d1,8), 
cisplatin (80 
mg/m2; d1); or 
mitomycin (6 
mg/m2; d1), 
ifosfamide (3 
g/m2; d1), 
cisplatin (50 
mg/m2; d1); or 
mitomycin (6 
mg/m2; d1), 
vinblastine (6 
mg/m2; d1), 
cisplatin (50 
mg/m2; d1); 
number of 
cycles/interval 
unknown 
0 Yes No 
Poor 
accrual 
3·9 
 Accru
al 
years 
Numb
er of 
patien
ts 
Clinic
al 
stage 
Preoperative 
chemotherapy 
used (dose per 
cycle) 
Postoperat
ive 
chemother
apy cycles 
planned 
Postoperat
ive 
radiothera
py planned 
Reach
ed 
target 
accrua
l 
Stopping 
reason 
Medi
an 
follo
w-up 
(years
) 
MRC 
LU2228 
1997
–
2005 
519 I–III 
Mitomycin (8 
mg/m2; first 2 
cycles only), 
vinblastine (6 
mg/m2; max 
10 mg), 
cisplatin (50 
mg/m2); or 
mitomycin (8 
mg/m2; first 2 
cycles only), 
ifosfamide (3 
g/m2), cisplatin 
(50 mg/m2); or 
vinorelbine (30 
mg/m2; d1,8; 
max 60 mg), 
cisplatin (80 
mg/m2; d1); or 
paclitaxel (175 
mg/m2), 
carboplatin 
(AUC=5); or 
gemcitabine 
(1250 mg/m2; 
d1,8), cisplatin 
(80 mg/m2; 
d1); or 
docetaxel (75 
mg/m2), 
carboplatin 
(AUC=6); 3 
cycles every 3 
weeks 
0 
Yes, if 
surgery 
incomplete 
or 
progressio
n 
Yes NA 7·6 
SWOG 
S990029 
1999
–
2004 
354 
IB–
IIIA 
Paclitaxel (225 
mg/m2), 
carboplatin 
(AUC=6); 3 
cycles every 3 
weeks 
0 No No 
Positive 
results of 
adjuvant 
chemother
apy trials 
5·5 
 Accru
al 
years 
Numb
er of 
patien
ts 
Clinic
al 
stage 
Preoperative 
chemotherapy 
used (dose per 
cycle) 
Postoperat
ive 
chemother
apy cycles 
planned 
Postoperat
ive 
radiothera
py planned 
Reach
ed 
target 
accrua
l 
Stopping 
reason 
Medi
an 
follo
w-up 
(years
) 
China 
200230 
1999
–
2004 
55 IIIA 
Docetaxel (75 
mg/m2; d1), 
carboplatin 
(AUC=5; d1); 2 
cycles every 3 
weeks 
0 
Yes, if 
surgery 
incomplete 
No 
Positive 
results of 
adjuvant 
chemother
apy 
trials/poor 
accrual 
7·8 
China 
200531 
1999
–
2004 
40 IIIA 
Gemcitabine 
(1200–1250 
mg/m2; d1,8), 
cisplatin (30 
mg/m2; d1–3); 
or gemcitabine 
(1200–1250 
mg/m2; d1,8), 
carboplatin 
(AUC=5; d1); 2 
cycles every 3 
weeks 
2 to 
responders 
No No 
Poor 
accrual 
3·3 
ChEST32 
2000
–04 
270 
IB–
IIIA 
Gemcitabine 
(1250 mg/m2; 
d1,8), cisplatin 
(75 mg/m2; 
d1); 3 cycles 
every 3 weeks 
0 No No 
Positive 
results of 
adjuvant 
chemother
apy trials 
3·10 
NATCH33 
2000
–07 
413 
IA-
IIIA 
Paclitaxel (200 
mg/m2), 
carboplatin 
(AUC=6); 3 
cycles every 3 
weeks 
0 
Yes, if 
pathologic
al pN2 
Yes NA 4·8 
NA=not applicable. AUC=area under the curve. 
Table options 
Data on age, sex, histology, and stage were provided for all but one trial,
20
 and performance status 
for 11 trials (table 2).
21, 23, 25, 26, 27, 28, 29, 30, 32, 33 and 38
 Based on the available data, patients were mostly 
men (80%) with a median age of 62 years (IQR 55–68) and good performance status (88%). They 
had mainly clinical stage IB–IIIA tumours (93%) that were predominantly squamous cell 
carcinomas (50%) or adenocarcinomas (29%). The median follow-up of all patients was 6 years 
(IQR 4·2–8·2; table 1). 
Table 2.  
Characteristics of included patients 
 
Surgery Chemotherapy plus surgery 
Age, years 
<60 450 (38%) 486 (42%) 
60–64 239 (20%) 202 (17%) 
65–69 259 (22%) 251 (22%) 
≥70 244 (20%) 224 (19%) 
Unknown 2 (<1%) 2 (<1%) 
Sex 
Male 970 (81%) 918 (79%) 
Female 221 (19%) 244 (21%) 
Unknown 3 (<1%) 3 (<1%) 
Histology 
Adenocarcinoma 353 (29%) 327 (28%) 
Squamous 616 (52%) 573 (49%) 
Large cell 49 (4%) 78 (7%) 
Other 162 (14%) 176 (15%) 
Unknown 14 (1%) 11 (1%) 
Clinical stage 
IA 63 (5%) 71 (6%) 
IB 545 (46%) 501 (43%) 
IIA 21 (2%) 29 (3%) 
 
Surgery Chemotherapy plus surgery 
IIB 309 (26%) 278 (24%) 
IIIA 246 (21%) 270 (24%) 
IIIB 4 (<1%) 9 (<1%) 
IV 0 (<1%) 3 (<1%) 
Unknown 6 (<1%) 4 (<1%) 
Performance status 
0 471 (43%) 463 (43%) 
1 514 (46%) 494 (45%) 
2+ 123 (11%) 125 (12%) 
Unknown 4 (<1%) 4 (<1%) 
Data are n (%). Data for all characteristics, except performance status, were available for 14 
of the 15 trials (99% of all patients). For performance status, data were available for 11 of 
the 15 trials (92% of all patients). 
Table options 
Survival results were based on 15 randomised controlled trials (2385 patients, 1427 deaths) and 
show a clear benefit of preoperative chemotherapy (HR 0·87, 95% CI 0·78–0·96; p=0·007; Figure 
1 and Figure 2). This represents a 13% reduction in the relative risk of death, translating to a 5% 
absolute improvement in survival at 5 years (from 40% to 45%). Despite design differences 
between trials, for example, a variety of chemotherapy regimens, exclusive use of preoperative 
chemotherapy, use of postoperative radiotherapy in both arms, and inclusion of all stages of patients 
or only a specific stage of patient, there was no clear evidence of statistical heterogeneity (p=0·18). 
 Figure 1.  
Effect of preoperative chemotherapy on survival 
Each square denotes the HR for that trial comparison with the horizontal lines showing the 95% and 
99% CIs. The size of the square is directly proportional to the amount of information contributed by 
the trial. The black diamond gives the pooled HR from the fixed effect model; the centre of this 
diamond denotes the HR and the extremities the 95% CI. O–E=observed minus expected. 
HR=hazard ratio. MIP=mitomycin, ifosphamide, cisplatin. SWOG=South West Oncology Group. 
JCOG=Japanese Cancer Oncology Group. MRC=Medical Research Council. BLT=Big Lung Trial. 
ChEST=Chemotherapy for Early Stages Trial. NATCH=Neoadjuvant/Adjuvant Trial of 
Chemotherapy. df=degrees of freedom. *Number of events/number entered. 
 Figure 2.  
Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to 
survival 
There is no clear evidence that the effect of chemotherapy on survival differed according to whether 
chemotherapy was given preoperatively or both preoperatively and postoperatively (interaction 
p=0·23), the number of preoperative chemotherapy cycles (interaction p=0·68), the type of 
chemotherapy regimen (interaction p=0·94), the number of chemotherapy agents per regimen 
(interaction p=0·84), or both the type of chemotherapy regimen and number of agents (interaction 
p=0·79; table 3). Analyses of the type of regimen, the number of agents per regimen, and both the 
type of regimen and number of agents were repeated only in those trials that gave platinum-based 
regimens, and gave similar results (interactions p=0·91, p=0·60, and p=0·62 respectively; table 3). 
We did not identify evidence of a difference in effect of chemotherapy on survival by whether 
regimens were cisplatin or carboplatin-based (interaction p=0·48) or whether postoperative 
radiotherapy was used (interaction p=0·87; table 3). 
Table 3.  
Effect of preoperative chemotherapy by prespecified trial group 
  
Number 
of trials 
Number of 
deaths/patients 
Hazard 
ratio 
(95%CI), p 
value 
Heterogeneity 
p value 
F ratio p 
value 
Interaction 
p value 
Survival by planned chemotherapy schedule (n=15 trials) 0·32 0·23 
 
Preoperative 
chemotherapy 
10 1045/1883 0·90 
(0·80–
0·10 
  
  
Number 
of trials 
Number of 
deaths/patients 
Hazard 
ratio 
(95%CI), p 
value 
Heterogeneity 
p value 
F ratio p 
value 
Interaction 
p value 
only 1·02), 0·09 
 
Preoperative and 
postoperative 
chemotherapy 
(to responders) 
5 382/502 
0·78 
(0·64–
0·95), 0·02 
0·62 
  
Survival by number of preoperative chemotherapy cycles (n=14 trials) 0·74 0·68 
 
2 cycles 6 418/576 
0·89 
(0·74–
1·08), 0·25 
0·39 
  
 
3 cycles 8 1002/1799 
0·85 
(0·75–
0·96), 0·01 
0·10 
  
Survival by chemotherapy regimen (n=14 trials) 
0·96 (all 
trials), 0·94 
(platinum-
only trials) 
0·95 (all 
trials), 0·91 
(platinum-
only trials) 
 
Platinum plus 
second 
generation 
chemotherapy 
7 543/694 
0·86 
(0·72–
1·02), 0·08 
0·03 
  
 
Platinum plus 
third generation 
chemotherapy 
6 801/1540 
0·85 
(0·74–
0·97), 0·02 
0·57 
  
 
Non-platinum 
chemotherapy 
1 38/62 
0·95 
(0·50–
1·79), 0·87 
NA 
  
Survival by the number of chemotherapy agents (n=15 trials) 
0·90 (all 
trials), 0·70 
(platinum-
only trials) 
0·84 (all 
trials), 0·60 
(platinum-
only trials) 
 
Non platinum 
single agent 
regimen 
1 38/62 
0·95 
(0·50–
1·79), 0·87 
NA 
  
  
Number 
of trials 
Number of 
deaths/patients 
Hazard 
ratio 
(95%CI), p 
value 
Heterogeneity 
p value 
F ratio p 
value 
Interaction 
p value 
 
Doublet regimen 9 907/1702 
0·88 
(0·78–
1·01), 0·06 
0·42 
  
 
Triplet regimen 5 475/611 
Fixed 
effect 0·83 
(0·69–
1·00), 
0·05; 
random 
effects 
0·79 
(0·53–
1·18), 0·25 
0·01 
  
Survival by chemotherapy regimen and number of chemotherapy agents 
(n=14 trials) 
0·89 (all 
trials), 0·95 
(platinum-
only trials) 
0·79 (all 
trials), 0·62 
(platinum-
only trials) 
 
Non-platinum 
single agent 
regimen 
1 38/62 
0·95 
(0·50–
1·79), 0·87 
NA 
  
 
Platinum second 
generation, 
doublet 
2 68/83 
1·08 
(0·66–
1·76), 0·76 
0·42 
  
 
Platinum second 
generation, 
triplet 
5 475/611 
Fixed 
effect 0·83 
(0·69–
1·00), 
0·05; 
random 
effects 
0·79 
(0·53–
1·18), 0·25 
0·01 
  
 
Platinum third 
generation, 
doublet 
6 801/1540 
0·85 
(0·74–
0·97), 0·02 
0·57 
  
  
Number 
of trials 
Number of 
deaths/patients 
Hazard 
ratio 
(95%CI), p 
value 
Heterogeneity 
p value 
F ratio p 
value 
Interaction 
p value 
Survival by cisplatin or carboplatin regimen (n=12 trials) 0·54 0·48 
 
Cisplatin-based 7 830/1289 
0·83 
(0·72–
0·95), 0·01 
0·08 
  
 
Carboplatin-
based 
5 492/905 
0·90 
(0·75–
1·07), 0·23 
0·88 
  
Survival by planned postoperative radiotherapy (n=15 trials) 0·64 0·57 
 
No postoperative 
radiotherapy 
given 
8 431/852 
0·83 
(0·68–
1·00), 0·05 
0·40 
  
 
Postoperative 
radiotherapy 
given 
7 996/1533 
0·88 
(0·78–
1·00), 0·05 
0·09 
  
Survival by whether trial stopped early (all trials; n=15 trials) 0·10 0·05 
 
Reached target 
accrual 
3 800/1287 
0·90 
(0·79–
1·04), 0·16 
0·66 
  
 
Stopped for 
benefit of 
chemotherapy 
2 92/119 
0·48 
(0·31–
0·74), 
<0·001 
0·43 
  
 
Stopped for high 
progression on 
chemotherapy 
arm 
1 16/26 
1·08 
(0·41–
2·90), 0·87 
NA 
  
 
Stopped for poor 
accrual/positive 
adjuvant trials 
9 519/953 
0·88 
(0·74–
1·05), 0·17 
0·31 
  
NA=not applicable. 
Although the interaction test is not significant there is some suggestion of a larger relative effect in 
trials where postoperative chemotherapy is given to responders (HR 0·78, 95% CI 0·64–0·95, 
p=0·02) than in those giving preoperative chemotherapy alone. Exploratory analyses examining 
whether such an approach modifies the effect of chemotherapy on time to local recurrence showed a 
similar pattern (preoperative chemotherapy HR 0·94, 95% CI 0·75–1·18, p=0·60; preoperative plus 
postoperative chemotherapy HR 0·73, 95% CI 0·50–1·07, p=0·11), but again no clear evidence of 
an interaction (p=0·26). However, for time to distant recurrence, there is evidence of a difference in 
effect by chemotherapy scheduling (p=0·05), with a substantially greater relative benefit in trials 
giving postoperative chemotherapy (HR 0·53, 95% CI 0·39–0·73, p<0·001) than in those using just 
preoperative chemotherapy (HR 0·78, 95% CI 0·63–0·96, p=0·02). 
12 trials did not reach their target accrual. Two
21 and 22
 closed early after recording a benefit of 
chemotherapy, one
20
 due to high progression rates in the chemotherapy arm, six due to poor 
accrual
24, 25, 26, 27, 31 and 38
 and three due to positive results in postoperative chemotherapy trials.
29, 
30 and 32
 Based on all trials, although we found some evidence of a difference in effect by the reason 
for early stopping of trials, small trials with extreme positive and negative estimates seem to 
strongly affect this result (table 3). An exploratory analysis, excluding smaller trials (100 patients or 
fewer), was based on 80% of the data (77% of all deaths),
23, 28, 29, 32 and 33
 and showed no clear 
difference in effect between trials stopping early and those reaching their target accrual (interaction 
p=0·24). 
We did not identify clear evidence that the effect of preoperative chemotherapy on survival differed 
by age, age group, performance status, or histology (figure 3). Although, overall, there is no 
evidence of a difference in effect by sex, there is heterogeneity in the interaction (figure 3). Some 
trials suggest the effect might be greater in women and others in men, but it is not clear why. Also, 
there was a significant interaction between the effect resection rates in both arms. The remaining 
seven trials
24, 25, 26, 28, 30, 32 and 38
 represented less than half of the total data and, with possible 
variation in the classification of extent of incomplete resection, this analysis was deemed unreliable. 
Based on all 11 trials, there was no evidence of an effect of preoperative chemotherapy on complete 
resection (OR 0·88, 95% CI 0·68–1·14, p=0·33; appendix), but the effect did vary between trials 
(heterogeneity p=0·006). This variation might relate to differences in the types of patients or 
surgery, because the baseline complete resection rate for control patients ranged from 67% to 95%, 
with the exception of one trial
21
 where it was substantially lower (31%). 
Recurrence-free survival data were available for 14 trials
20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 and 38
 (2326 
patients, 1524 events). The findings provide clear evidence of a benefit of preoperative 
chemotherapy (HR 0·85, 95% CI 0·76–0·94, p=0·002, heterogeneity p=0·41, figure 4), translating 
to an absolute improvement in recurrence-free survival of 6% at 5 years, taking it from 30% to 
36%. 
of preoperative chemotherapy and stage in the ChEST trial,
32
 but not in the other trials, or across all 
trials (interaction p=0·83; appendix). An exploratory analysis, splitting clinical stage I disease into 
IA and IB, also identified an interaction between the treatment effect and clinical stage in the 
ChEST trial, but not across trials (p=0·64, heterogeneity p=0·22). Thus, the overall HR of 0·87 was 
applied to the control group survival for each stage, giving an absolute survival improvement at 5 
years of 5% for all stages, taking it from 50% to 55% in stage I, from 30% to 35% in stage II, and 
from 20% to 25% in stage III. However, most patients in stage I are IB (89%), in stage II are IIB 
(92%), and in stage III are IIIA (98%), therefore we can be most confident of results for these 
patients. 
Figure 3.  
Forest plot of the interactions between the effect of preoperative chemotherapy on survival 
and covariates 
The circles represent (fixed effect) meta-analyses of the HRs representing the interactions 
between the effect of chemotherapy and patient characteristics; the horizontal line shows the 
95% CI. HR=hazard ratio. 
Mortality within 30 days of surgery could be calculated for nine trials,
23, 25, 26, 28, 29, 30, 31, 32 and 38
 
(1611 patients, 52 deaths) that supplied date of surgery. Four of these
26, 30, 31 and 38
 had no deaths 
within 30 days of surgery in either arm and an OR was not estimable. Overall, we did not identify a 
difference between treatment arms (OR 1·48, 95% CI 0·85–2·58, p=0·17; heterogeneity p=0·45, 
appendix). Based on all 15 trials (2381 patients, 254 deaths), we also did not identify a deleterious 
effect of preoperative chemotherapy on mortality within 6 months of randomisation (OR 0·88, 
95%CI 0·67–1·14, p=0·33; heterogeneity p=0·60). 
11 trials
21, 23, 24, 25, 26, 28, 29, 30, 31, 32 and 38
 (1778 patients) provided data on extent of resection. For the 
overall resection rate, ORs could not be estimated for four trials
21, 23, 29 and 31
 because they had 100%  
 
Figure 4.  
Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to 
distant and locoregional recurrence and recurrence-free survival 
Analyses of recurrence outcomes were calculated from a landmark time of 6 months from 
the date of randomisation; for this reason time on the x-axis starts at 6 months. 
Data on both time to locoregional recurrence and distant recurrence were available for 13 trials
20, 21, 
23, 24, 25, 26, 27, 28, 29, 30, 31, 32 and 38
 and 1913 patients (426 events and 526 events respectively). In these 
patients, 630 (33%) were alive and free from disease. For the remaining 1283 patients, the first 
events recorded were locoregional recurrence for 305 (24%), distant recurrence for 397 (31%), both 
locoregional and distant recurrence for 115 (9%), and death without recurrence for 466 (36%; 
appendix). There is clear evidence of a benefit of preoperative chemotherapy on time to distant 
recurrence (HR 0·69, 95% CI 0·58–0·82; p<0·001; heterogeneity p=0·40; figure 4), but the effect 
on time to locoregional recurrence was less clear (HR 0·88, 95% CI 0·73–1·07; p=0·20; 
heterogeneity p=0·89; figure 4). These findings translate into an absolute improvement in time to 
distant recurrence of 10% at 5 years (from 60% to 70%). There is a potential improvement on time 
to locoregional recurrence of 3% at 5 years. 
Discussion 
Based on data from 15 randomised trials (92% of all patients who were randomised), we have 
shown a 5% absolute benefit of preoperative chemotherapy on 5 year survival in patients with 
resectable NSCLC. There was no clear evidence of a difference in this effect by treatment type, 
scheduling, trial design differences, or by patient characteristics, although the results are most 
reliable for stage IB–IIIA. There seemed to be no excess of early mortality in the preoperative 
chemotherapy arm as a result of deferred surgery. 
Although this meta-analysis included most patients known to have been randomised, four eligible 
trials (198 patients) could not be included. We could estimate an HR
39
 for survival for one trial of 
90 patients,
36
 but not the remaining three trials. Two of these
34 and 35
 (106 patients) did not report the 
appropriate information, and one (two patients) was unpublished.
37
 When the single estimated HR 
was combined with the overall result for the meta-analysis, the effect on survival remained the same 
(HR 0·87, p=0·006), but being based on 96% of patients who were randomised, it provides more 
convincing evidence of a benefit of preoperative chemotherapy. This systematic review and meta-
analysis will be updated if further eligible trials are identified. 
One reason for using preoperative chemotherapy is that it might make tumours more operable, 
potentially improving the likelihood of a complete resection. Conversely, delays to surgery could 
make it harder to achieve a complete resection. However, we did not identify clear evidence of a 
positive or negative effect of chemotherapy on the complete resection rate or a benefit on 
locoregional recurrence. However, we did note a 10% absolute benefit of preoperative 
chemotherapy on distant recurrence at 5 years, suggesting that it might have greater potential to 
eradicate micrometastases than postoperative chemotherapy, where the absolute benefit was 5% at 5 
years.
4
 
Comparing the effect of preoperative and postoperative chemotherapy directly, using data from this 
meta-analysis and two previous ones of postoperative chemotherapy in NSCLC proved problematic. 
Although it was possible to make the datasets comparable in terms of the regimens used, we could 
not make them comparable in terms of their patient characteristics, particularly stage. Only 
pathological stage was available for the postoperative chemotherapy meta-analysis, and agreement 
between clinical and pathological staging in the control group patients of the current meta-analysis 
was only around 60%. However, survival in the control group of the present meta-analysis is 
somewhere between that noted for patients receiving surgery alone and those receiving surgery plus 
radiotherapy as definitive treatment,
4
 suggesting that the present population spans the two. 
Although this difference makes a formal indirect comparison of the effects of preoperative and 
postoperative chemotherapy difficult, the benefit noted is on a similar scale. Others have attempted 
formal comparison based on aggregate data
8
 and concluded the effect of chemotherapy on overall or 
recurrence-free survival is similar, irrespective of chemotherapy timing. However, they did not 
include key large trials, published more recently, and have included a trial confounded by the use of 
radiotherapy in only one arm.
40
 
We included one three-arm trial (NATCH
33
) with both preoperative and postoperative 
chemotherapy arms, but because it was underpowered, the authors did not report their direct 
comparison. Nevertheless, they provided us with analyses showing similar effects of preoperative 
and postoperative chemotherapy on survival (HR 0·93, 95% CI 0·71–1·23, p=0·61) and recurrence-
free survival (HR 0·88, 95% CI 0·68–1·13, p=0·31; Rosell R, unpublished). Similarly, a recent 
trial
41
 (198 patients), of preoperative versus postoperative chemotherapy reported no difference in 
disease-free survival (HR 0·88, 95% CI 0·58–1·33, p=0·54), although power could also be an issue 
in this trial. 
The findings of NATCH
33
 showed a difference in treatment compliance between the preoperative 
(90%) and the postoperative (60%) chemotherapy arms. Of the trials included in our report, the 
ten
20, 22, 23, 24, 25, 26, 28, 29, 32 and 33
 that reported the number of patients receiving all scheduled 
preoperative chemotherapy (2–3 cycles), identified a similarly high compliance rate with 
preoperative chemotherapy (mean compliance rate 85%, range 71–100%). By contrast, for the 14 
trials in the postoperative chemotherapy systematic review
4
 that reported patients receiving 
scheduled chemotherapy (2–6 cycles), the mean compliance rate was somewhat lower (62%, range 
41–98%). This implies that patients might receive more of their planned chemotherapy if it is given 
before surgery. 
The results so far seem to suggest similar effects with either preoperative or postoperative 
chemotherapy, giving a choice of treatment options. Clinicians might consider that preoperative 
chemotherapy is preferable for poorer prognosis patients with larger, more advanced stage tumours, 
less able to tolerate chemotherapy after surgery, or in regions where surgery waiting lists are longer. 
Postoperative chemotherapy might be preferred by surgeons and by patients wishing to have 
potentially curative treatment immediately, or for those with earlier stage disease. It also allows for 
more reliable pathological staging to establish if subsequent chemotherapy is appropriate. 
Because this meta-analysis shows that preoperative chemotherapy has a greater effect on 
metastases, and a previous one
4
 shows that postoperative chemotherapy has a greater effect on local 
control, it is tempting to speculate that combined preoperative and postoperative chemotherapy 
would confer a greater benefit on local and distant control and survival. This is not entirely borne 
out by the present survival results by chemotherapy scheduling and generally only those patients 
responding to preoperative chemotherapy were also given postoperative chemotherapy such that 
most would have received preoperative chemotherapy alone. However, exploratory analyses do 
suggest a synergistic effect of combining preoperative and postoperative chemotherapy on time to 
metastases. However, it should be noted that more cycles of chemotherapy were planned in the 
trials of combined preoperative and postoperative chemotherapy (2–3 plus 2–3 cycles 
postoperatively) compared with those of just preoperative chemotherapy (2–3). Moreover, a 
recently reported trial that compared the use of preoperative chemotherapy plus postoperative 
chemotherapy
42
 to responders with postoperative chemotherapy in 528 similar patients identified no 
evidence that preoperative plus postoperative chemotherapy was better (HR 1·01, 95% CI 0·79–
1·30, p=0·92). Nevertheless, further head-to-head comparisons of these approaches might be 
warranted. 
The potential benefit of preoperative chemotherapy would need to be balanced against possible 
toxic effects. However, although we were unable to assess toxic effects at the patient level in this 
study, trial reports for 13 of the included trials described mild or acceptable toxic effects and that 
chemotherapy was generally well tolerated. Further questions regarding which drugs to use, the 
duration of chemotherapy, and if the effect might be modified by predictive genetic biomarkers will 
need to be answered by new or ongoing trials. Nevertheless, these results provide the most complete 
evidence so far of the effects of preoperative chemotherapy, showing a significant improvement in 
overall survival, time-to-distant recurrence, and recurrence-free survival. 
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